articleEuropean Heart JournalMay 7, 2025GREEN OA

Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statement

SRStefano RomeoAVAntonio Vidal‐PuigMHMansoor HusainRSRexford S. AhimaMAMarcello Arca

Karolinska University Hospital · Sahlgrenska University Hospital · +51 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Obesity rates have surged since 1990 worldwide. This rise is paralleled by increases in pathological processes affecting organs such as the heart, liver, and kidneys, here termed systemic metabolic disorders (SMDs). For clinical management of SMD, the European Atherosclerosis Society proposes a pathophysiology-based system comprising three stages: Stage 1, where metabolic abnormalities such as dysfunctional adiposity and dyslipidaemia occur without detectable organ damage; Stage 2, which involves early organ damage manifested as Type 2 diabetes, asymptomatic diastolic dysfunction, metabolic-associated steatohepatitis (MASH), and chronic kidney disease (CKD); and Stage 3, characterized by more advanced organ…

Citation impact

42
total citations
FWCI
38.89
Percentile
100%
References
334
Citations per year

Authors

62

Topics & keywords

Topics
Keywords
  • Medicine
  • Consensus conference
  • Statement (logic)
  • Intensive care medicine
  • Internal medicine
  • Law
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding